Integrated viral clearance strategies-reflecting on the present, projecting to the future.

Viral clearance and inactivation are critical steps in ensuring the safety of biological products derived from mammalian cell culture and are a component of an adventitious agent control strategy which spans both upstream and downstream processes. Although these approaches have been sufficient to support the development of biologics to date, the empirical and semi-quantitative nature of the approach leaves some potential gaps. For example, the concept of performing a quantitative risk assessment for the downstream components of virus safety was introduced in ICH Q5A for XMuLV. An ideal future state would be to perform a similar quantitative risk assessment for a range of viruses based on an assessment of potential virus risk in both upstream and downstream processes. This assessment combined with an integrated control strategy (including monitoring) would be extremely beneficial in minimizing potential adventitious agent risks. Significant progress has been achieved towards this goal in the last several years including recent advances in quantification of virus sequences in cell banks (ADVTIG), development of truly modular or generic viral clearance claims for specific unit operations, enhanced controls of upstream media (HTST/nanofiltration) and the use of RVLP for in-process monitoring. The recent shift towards continuous processing has the potential to enhance the criticality of in-line monitoring and the complexity of viral clearance and inactivation (owing to a wide range of potential 'worst case' viral clearance scenarios). However, gaps exist in, firstly, the ability to quantify potential virus risk levels in process streams in real-time, secondly, mechanistic understanding of virus/chromatography media interactions, and thirdly, mechanistic understanding of virus/filter interactions. Some new technologies may also need to be developed to allow for real-time confirmation of virus inactivation and clearance to support process development (both batch and continuous) and assessment of the impact of process deviations during manufacturing. This review paper provides an overview of the current state of an overall integrated control strategy for upstream and downstream processing and highlights the investments that could be pursued to achieve the future state of a quantitative virus risk assessment for a range of viruses. One potential approach to address these gaps is the use of data mining from large, comprehensive and diverse data sets to establish heuristic rules for virus detection, clearance and inactivation followed by specific hypothesis-driven experiments for cases that fall outside of the normal paradigm. Once this approach reaches a mature state suitable for implementation, there is an opportunity to update regulatory guidance (e.g. ICH Q5A) accordingly.

[1]  R. Pepinsky,et al.  Biochemical analysis of retroviral structural proteins to identify and quantify retrovirus expressed by an NS0 murine myeloma cell line. , 2000, Journal of biotechnology.

[2]  Kurt Brorson,et al.  Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO‐cell derived biotherapeutics , 2009, Biotechnology and bioengineering.

[3]  John E. Schiel,et al.  State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3. Defining the Next Generation of Analytical and Biophysical Techniques , 2015 .

[4]  Hazel Aranha,et al.  Viral clearance for biopharmaceutical downstream processes , 2015 .

[5]  Laurent Mallet,et al.  Need for New Technologies for Detection of Adventitious Agents in Vaccines and Other Biological Products , 2014, PDA Journal of Pharmaceutical Science and Technology.

[6]  Kurt Brorson,et al.  Session 2: Company-Specific Data on Cycled Resin Testing , 2016, PDA Journal of Pharmaceutical Science and Technology.

[7]  Arifa S. Khan,et al.  New Technologies and Challenges of Novel Virus Detection , 2014, PDA Journal of Pharmaceutical Science and Technology.

[8]  Dayue Chen,et al.  Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[9]  K. Brorson,et al.  Proceedings of the 2009 Viral Clearance Symposium. , 2010, Developments in biologicals.

[10]  Rachel Specht,et al.  Session 4.1: Case Studies of Application of Generic Claims and QbD for Viral Clearance , 2016, PDA Journal of Pharmaceutical Science and Technology.

[11]  David J Roush,et al.  Targeted purification development enabled by computational biophysical modeling , 2015, Biotechnology progress.

[12]  Crystal Jaing,et al.  Viral Nucleic Acids in Live-Attenuated Vaccines: Detection of Minority Variants and an Adventitious Virus , 2010, Journal of Virology.

[13]  Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin , 2016 .

[14]  Sarah A Johnson,et al.  Adapting viral safety assurance strategies to continuous processing of biological products , 2017, Biotechnology and bioengineering.

[15]  Eva Gefroh,et al.  Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies , 2014, PDA Journal of Pharmaceutical Science and Technology.

[16]  R. Kiss Practicing Safe Cell Culture: Applied Process Designs for Minimizing Virus Contamination Risk , 2011, PDA Journal of Pharmaceutical Science and Technology.

[17]  Min Zhang,et al.  Quality by design approach for viral clearance by protein a chromatography , 2013, Biotechnology and bioengineering.

[18]  Matthew R Brown,et al.  Mycoplasma Clearance and Risk Analysis in a Model Bioprocess , 2017, PDA Journal of Pharmaceutical Science and Technology.

[19]  Y. Chisti,et al.  Biochemical engineering in biotechnology (Technical Report) , 1994 .

[20]  H. Willkommen Session 2/3: Integrated Viral Clearance Strategy and Case Studies , 2015, PDA Journal of Pharmaceutical Science and Technology.

[21]  D. Vacante,et al.  Protocol for Evaluation of Virus Inactivation Using Low-pH Treatment , 2014, PDA Journal of Pharmaceutical Science and Technology.

[22]  Arifa S Khan,et al.  Advanced Virus Detection Technologies Interest Group (AVDTIG): Efforts on High Throughput Sequencing (HTS) for Virus Detection , 2016, PDA Journal of Pharmaceutical Science and Technology.

[23]  Matthew R Brown,et al.  Adapting viral safety assurance strategies to continuous processing of biological products. , 2017, Biotechnology and bioengineering.

[24]  S. Lute,et al.  Development of a modular virus clearance package for anion exchange chromatography operated in weak partitioning mode , 2015, Biotechnology progress.

[25]  Edward J. O'Brien,et al.  Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome , 2013, Nature Biotechnology.

[26]  Kurt Brorson,et al.  Impact of cell culture process changes on endogenous retrovirus expression. , 2002, Biotechnology and bioengineering.

[27]  C. Petropoulos,et al.  Chinese hamster ovary cells contain transcriptionally active full-length type C proviruses , 1994, Journal of virology.

[28]  S. Lute,et al.  Analysis of viral clearance unit operations for monoclonal antibodies , 2010, Biotechnology and bioengineering.

[29]  Christina Carbrello,et al.  Protection of bioreactor culture from virus contamination by use of a virus barrier filter , 2015, BMC Proceedings.

[30]  K. Vijayaragavan,et al.  Experimental and computational surface hydrophobicity analysis of a non-enveloped virus and proteins. , 2017, Colloids and surfaces. B, Biointerfaces.

[31]  Matthew R Brown,et al.  The step-wise framework to design a chromatography-based hydrophobicity assay for viral particles. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[32]  Rachel Specht,et al.  Session 4.2: Viral Spiking, Viral Preparation, and Upstream Risk Mitigation Strategies , 2016, PDA Journal of Pharmaceutical Science and Technology.

[33]  O. Galperina,et al.  Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration , 2016, PDA Journal of Pharmaceutical Science and Technology.

[34]  J. Hughes,et al.  Impact of virus preparation quality on parvovirus filter performance , 2013, Biotechnology and bioengineering.

[35]  R. Nims,et al.  Gamma-irradiation of serum for the inactivation of adventitious contaminants. , 2010, PDA journal of pharmaceutical science and technology.

[36]  K. Brorson,et al.  Meeting Report: 2015 PDA Virus & TSE Safety Forum , 2016, PDA Journal of Pharmaceutical Science and Technology.

[37]  K. Brorson,et al.  Meeting Report: 2013 PDA Virus & TSE Safety Forum , 2014, PDA Journal of Pharmaceutical Science and Technology.

[38]  Kurt Brorson,et al.  A Novel, Q‐PCR Based Approach to Measuring Endogenous Retroviral Clearance by Capture Protein A Chromatography , 2009, Biotechnology and bioengineering.

[39]  Z. Wen,et al.  Identification and Root Cause Analysis of Cell Culture Media Precipitates in the Viral Deactivation Treatment with High-Temperature/Short-Time Method , 2013, PDA Journal of Pharmaceutical Science and Technology.

[40]  Matthew R Brown,et al.  A step‐wise approach to define binding mechanisms of surrogate viral particles to multi‐modal anion exchange resin in a single solute system , 2017, Biotechnology and bioengineering.

[41]  A. Zydney,et al.  Probing effects of pressure release on virus capture during virus filtration using confocal microscopy , 2015, Biotechnology and bioengineering.